Vanguard Group Inc. reduced its position in shares of Shire PLC (NASDAQ:SHPG) by 5.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,458,330 shares of the biopharmaceutical company’s stock after selling 84,304 shares during the period. Vanguard Group Inc. owned approximately 0.49% of Shire PLC worth $241,018,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in SHPG. BlackRock Inc. grew its holdings in Shire PLC by 4,217.7% during the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after acquiring an additional 1,400,275 shares during the period. Glenview Capital Management LLC acquired a new position in Shire PLC during the first quarter worth about $176,927,000. Jana Partners LLC acquired a new position in Shire PLC during the first quarter worth about $94,903,000. New South Capital Management Inc. acquired a new position in Shire PLC during the first quarter worth about $87,954,000. Finally, Northern Trust Corp grew its holdings in Shire PLC by 45.5% during the second quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock worth $216,064,000 after acquiring an additional 408,843 shares during the period. 19.28% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently issued reports on SHPG. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 target price on shares of Shire PLC in a report on Wednesday, July 12th. Cantor Fitzgerald set a $222.00 target price on Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a report on Friday, June 16th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $210.00 target price on shares of Shire PLC in a report on Thursday, July 13th. Finally, BTIG Research reaffirmed a “buy” rating and set a $242.00 target price on shares of Shire PLC in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $220.91.
Shares of Shire PLC (NASDAQ SHPG) opened at 154.07 on Friday. The firm’s 50-day moving average price is $153.54 and its 200-day moving average price is $165.14. The firm has a market capitalization of $45.89 billion, a price-to-earnings ratio of 68.94 and a beta of 1.63. Shire PLC has a 12 month low of $139.36 and a 12 month high of $194.60.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. On average, equities analysts anticipate that Shire PLC will post $14.93 earnings per share for the current year.
The firm also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a $0.1527 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is currently 41.07%.
ILLEGAL ACTIVITY NOTICE: “Shire PLC (SHPG) Shares Sold by Vanguard Group Inc.” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/10/14/shire-plc-shpg-shares-sold-by-vanguard-group-inc.html.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.